莎普爱思2025年预亏超2亿 股东减持与资金波动引关注

Core Viewpoint - The company Shapuaisi (603168) has announced a projected net profit loss of between 213 million to 319 million yuan for 2025, primarily due to goodwill impairment related to two hospitals [1][2]. Financial Performance - The company expects a net profit loss of 213 million to 319 million yuan for 2025, mainly due to goodwill impairment for its subsidiaries, Taizhou Women and Children's Hospital and Qingdao Shikang Eye Hospital [2]. - Despite achieving a net profit of 27.63 million yuan in the first three quarters of 2025 (a year-on-year increase of 189.85%), the overall annual performance is expected to turn negative due to the impairment [2]. Stock and Fund Performance - Shareholder reduction actions have been a point of market focus, with Shanghai Jingxing Industrial Investment Co., Ltd. reducing its holdings by 140,000 shares from October 2025 to January 2026, totaling 1.1656 million yuan [3]. - Another shareholder, Chen Dekang, has reduced his holdings multiple times in 2025, with a cumulative reduction exceeding 77 million yuan, indicating shifts in shareholder sentiment [3]. - In January 2026, there was a short-term fluctuation in fund flow, with a net inflow of 3.305 million yuan on January 6, followed by a net outflow of 2.963 million yuan on January 8, reflecting divided market sentiment [3]. Financial Condition - Goodwill impairment has become a significant factor affecting the company's performance, with a goodwill book value of 332 million yuan as of the end of 2024, accounting for 15.77% of total assets [4]. - If the hospital business does not meet expectations, further impairment may be necessary, impacting profitability stability [4]. Business Development - The clinical trial for atropine sulfate eye drops has completed participant enrollment as of May 2025, but subsequent approval results are still pending [5]. - The pharmaceutical industry is influenced by an aging population and policy support, necessitating attention to the company's product innovation and channel development progress for long-term prospects [5].